Inför Q1-rapporten räknar Analysguiden med tillväxt på samtliga marknader och en stärkt rörelsemargi...
Fastighetsbolaget Trianon redovisade hyresintäkter om 732,8 miljoner kronor under 2023.
Redeye provides its initial comments on yesterday evening’s news that Xbrane has received a CRL from...
Redeye anticipates that Physitrack will resume its sequential growth trajectory in Q1 2024, albeit w...
Vitrolife’s Q1 shows that the headwind for Genetics will likely last until mid-2024.
Redeye comments on Nepa ahead of its Q1 results (due 7 May).
Redeye comments on Scandion Oncology announcing a cSEK60m rights issue.
Redeye updates its estimates and valuation following ADDvise releasing its Q1 2024 report, which fea...
Elanders presented a mixed Q1 report, with a high single-digit organic sales decline, as Fashion saw...
Including Brage acquisition in our estimates Løvmeis exploration well in Q3'24 - the next big event ...
Redeye considers the declaration of intents for the TO6 warrants from Xspray's largest shareholders ...
Plejds nettoomsättning för det fjärde kvartalet 2023 uppgick till 159,0 MSEK (121,3), en ökning med ...
Flat organic sales growth, due to Genetics EBITDA revised down 1.
Redeye presents its preview of Sedana Medical’s Q1 2024 report, due on April 25.
Adj. EBITA SEK 180m (-16% vs. ABGSCe 214m) Consensus full-year EBITA should come down by mid-to-high...
Redeye comments on Safeture's Q1 2024 report, which was stable despite higher churn.
Redeye updates its outlook on Hansa Biopharma, anticipating improved launch support during 2024 and ...
Redeye provides a research update following the Q1 report recently published by Magle.
Redeye is encouraged to see progress in Impact Coatings’ Chinese coating center.
Q1e: Clean EBIT of PLN 87m Paper is improving – better demand and 10% supply cuts Fair value range o...